Cefdinir and Pregnancy
Animal studies on cefdinir and pregnancy show no negative effects on the fetus. As a result, the FDA has classified cefdinir as a pregnancy Category B medicine. However, since the drug has not actually been studied in humans, if you are taking cefdinir and pregnancy occurs, your healthcare provider will weigh the benefits to you against any possible risks to your unborn child before making a recommendation.
Cefdinir (Omnicef®) is considered a pregnancy Category B medicine by the U.S. Food and Drug Administration (FDA), which means that it has not been studied in pregnant women. However, when studied in pregnant animals, cefdinir showed no negative effects on the fetus.
The FDA uses a category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Pregnancy Category B is given to medicines that do not cause side effects to the fetus in animal studies but for which no human studies in pregnant women have been conducted.
However, it is important to note that animals do not always respond to medicines the same way that humans do. Therefore, a pregnancy Category B medicine may be given to a pregnant woman if the healthcare provider believes that the benefits to the mother outweigh any possible risks to the unborn child.
If you are taking cefdinir and pregnancy occurs, let your healthcare provider know. He or she will consider the benefits and risks of cefdinir during pregnancy before making a recommendation for your particular situation.